The recent development of commercial panel-based molecular diagnostics for the rapid detection of pathogens in positive blood culture bottles, respiratory specimens, stool, and cerebrospinal fluid has resulted in a paradigm shift in clinical microbiology and clinical practice. This review focuses on U.S. Food and Drug Administration (FDA)-approved/cleared multiplex molecular panels with more than five targets designed to assist in the diagnosis of bloodstream, respiratory tract, gastrointestinal, or central nervous system infections. While these panel-based assays have the clear advantages of a rapid turnaround time and the detection of a large number of microorganisms and promise to improve health care, they present certain challenges, including cost and the definition of ideal test utilization strategies (i.e., optimal ordering) and test interpretation.

中文翻译：

---

临床微生物学中基于综合症的基于面板的测试[评论]

用于快速检测阳性血培养瓶，呼吸道标本，粪便和脑脊液中病原体的基于商用面板的分子诊断技术的最新发展已导致临床微生物学和临床实践的范式转变。这篇综述的重点是美国食品药品监督管理局（FDA）批准/批准的多重分子检测板，其具有五个以上的靶标，旨在协助诊断血流，呼吸道，胃肠道或中枢神经系统感染。尽管这些基于面板的测定法具有快速周转时间和检测大量微生物的明显优势，并有望改善医疗保健，但它们也带来了某些挑战，包括成本和理想测试利用策略的定义（即，